Filters
Save & Share
Clear Filters
Location
Explore options near your center - or near your patient's home.
Diagnosis
Purpose of Trial
Filter and find trials based on their purpose.
Risk Level
Enter this patient's risk level (IPSS-R / IPSS-M).
Trials Near Add Your Location
Accepting patients
ELEMENT-MDS
Phase 3 Clinical Trial Comparing Luspatercept VS Epoetin Alfa in Patients with Very Low – Intermediate Risk MDS Who Are Not Transfusion Dependent
Learn more- Erythroid Maturation Agent (EMA)
- Erythropoiesis-Stimulating Agent (ESA)
- Red Blood Cell Stimulant
- Phase 3
Accepting patients
Bone Marrow & Kidney Transplant
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders (BMT)
Learn more- Allogeneic Stem Cell Transplant
- Phase 2
Accepting patients
Identifying Barriers to Allo Stem Cell Transplants
Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia
Learn more- Pre-Allogeneic Stem Cell Transplant
- Observational Trial
Accepting patients
Smart Immune
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Acute Leukemia After T Cell Depleted Allo-HSCT
Learn more- Phase 1/2
- Observational Trial
Accepting patients
DISC-0974
A Phase 1b/2a Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-0974 in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Learn more- Monoclonal Antibody
- Hemojuvelin (HJV)
- Monotherapy
- Randomization
- Phase 1/2
Not yet accepting
Abatacept in Double Cord Blood Unit Transplant
ABBA CORD: Double Umbilical Cord Blood Transplants With Abatacept for Graft Versus Host Disease Prophylaxis
Learn more- Immunomodulatory Drug
- T Cell
- Phase 2
Accepting patients
Biomarkers of Cardiovascular Disease in MDS
Defining Inflammatory Biomarkers of Cardiovascular Disease in Patients with Myelodysplastic Syndromes
Learn moreAccepting patients
KT-253
A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-253 in Adult Patients With High Grade Myeloid Malignancies and Acute Lymphocytic Leukemia, Lymphoma and Advanced Solid Tumors
Learn more- MDM2 Inhibitor
- Phase 1
Accepting patients
PROMISE
Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
Learn more- High Risk
- Observational
- Observational Trial